Sanofi (NASDAQ:SNY) said two phase 3 studies published in The Lancet and The Lancet Haematology, highlighted the potential of hemophilia prevention therapy fitusiran. Sanofi had gained the rights to ...

Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from ...

Two phase 3 trials of Sanofi’s small interfering RNA (siRNA) fitusiran have met their primary endpoints of significantly reducing the annualized bleeding rate of patients with hemophilia A or B.

Editor's note: This story has been updated from the previous version. The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 ...

Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe ...

Paris, France - September 7, 2017 - Sanofi alliance partner Alnylam Pharmaceuticals today provided an update on the clinical development program for fitusiran, an investigational RNAi therapeutic in ...

(Bloomberg) -- Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients greater ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off on ...

Please provide your email address to receive an email when new articles are posted on . The subcutaneously administered small interfering RNA therapy conferred a 90.8% reduction in the annualized ...

Paris, June 21, 2024. Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, ...